Rockefeller Capital Management L.P. Has $7.18 Million Holdings in PROCEPT BioRobotics Corporation $PRCT

Rockefeller Capital Management L.P. grew its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 2,727.2% in the 4th quarter, HoldingsChannel reports. The fund owned 228,186 shares of the company’s stock after buying an additional 220,115 shares during the period. Rockefeller Capital Management L.P.’s holdings in PROCEPT BioRobotics were worth $7,179,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PRCT. Alliancebernstein L.P. grew its position in PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after buying an additional 1,218,815 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in PROCEPT BioRobotics by 23.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock worth $70,315,000 after buying an additional 371,798 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of PROCEPT BioRobotics by 8.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after buying an additional 118,971 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in shares of PROCEPT BioRobotics by 11.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock valued at $47,841,000 after buying an additional 155,601 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Price Performance

PRCT opened at $21.49 on Friday. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $62.17. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -11.81 and a beta of 0.85. The firm’s fifty day moving average price is $25.40 and its two-hundred day moving average price is $27.66.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. During the same quarter in the prior year, the company earned ($0.45) EPS. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. As a group, analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research report on Thursday, April 30th. Oppenheimer reaffirmed a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Wells Fargo & Company cut their price target on PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating for the company in a research note on Thursday, February 26th. Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. Finally, Robert W. Baird began coverage on PROCEPT BioRobotics in a research note on Friday, March 6th. They issued a “neutral” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics has an average rating of “Hold” and a consensus price target of $40.42.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.